Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease

Bibliography

• Altschul R, Hoffer A, Stephen J. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955;54:558-9
   PubMed Web of Science ®Google Scholar
• Parsons WJ, Flinn J. Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid. AMA Arch Intern Med 1959;103:783-90
   PubMedGoogle Scholar
• Carlson L, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989;226:271-6
   PubMed Web of Science ®Google Scholar
• Carlson L. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005;258:94-114
   PubMed Web of Science ®Google Scholar
• Coronary Drug Project report on clofibrate and niacin. Atherosclerosis 1978;30:239-40
   PubMedGoogle Scholar
• Canner P, Berge K, Wenger N, Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-5
   PubMed Web of Science ®Google Scholar
• Carlson L, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988;223:405-18
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Selzer RH, Crawford DW, Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation 1993;88:20-8
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao X-Q, Chait A, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009; 361(22):2113-22
   Web of Science ®Google Scholar
• Lee JMS, Robson MD, Yu L-M, Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-94
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intimaa-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
   PubMed Web of Science ®Google Scholar
• Carlson L, Oro L. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 1962;172:641-5
   PubMed Web of Science ®Google Scholar
• Tunaru S, Kero J, Schaub A, PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-5
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol 2008;101(8 Suppl 1):S20-6
   PubMed Web of Science ®Google Scholar
• Jin F-Y, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells: implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-8
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Diffenderfer MR, Barrett PHR, Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apo B-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:1672-8
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010;31:149-64
   PubMed Web of Science ®Google Scholar
• Benyó Z, Gille A, Kero J, GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005;115:3634-40
   PubMed Web of Science ®Google Scholar
• Cheng K, Wu T-J, Wu KK, Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc Natl Acad Sci USA2006;103(17):6682-7
   Web of Science ®Google Scholar
• Morrow J, Awad J, Oates J, Roberts LN. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992;98:812-15
   PubMed Web of Science ®Google Scholar
• Paolini J, Bays H, Ballantyne C, Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin 2008;26:547-60
   PubMed Web of Science ®Google Scholar
• Maccubbin D, Bays HE, Olsson AG, Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-70
   PubMed Web of Science ®Google Scholar
• Carlson L, Olsson A. Effect of hypolipidemic drugs on serum lipoproteins. Prog Biochem Pharmacol 1979;15:238-57
   PubMedGoogle Scholar
• Norquist JM, Watson DJ, Yu Q, Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin 2007;23:1549-60
   PubMed Web of Science ®Google Scholar
• Kaijser L, Eklund B, Olsson A, Carlson L. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979;57:114-17
   PubMedGoogle Scholar
• Lai E, Schwartz JI, Dallob A, Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets 2010;21(3):191-8
   Google Scholar
• Lauring B, Dishy V, Luo W-L, Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. J Clin Pharmacol 2009;49:1426-35
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar